Last updated on April 2019

Study Evaluating Safety Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer

Brief description of study

A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer

Detailed Study Description

This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 administered as a short term intravenous (IV) infusion in subjects with small cell lung cancer. AMG 757 is a Half Life Extended (HLE) Bispecific T cell engager (BiTE) targeting delta-like protein 3 (DLL3)

Clinical Study Identifier: NCT03319940

Contact Investigators or Research Sites near you

Start Over

Research Site

Villejuif, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.